JP2024543967A5 - - Google Patents

Info

Publication number
JP2024543967A5
JP2024543967A5 JP2024532457A JP2024532457A JP2024543967A5 JP 2024543967 A5 JP2024543967 A5 JP 2024543967A5 JP 2024532457 A JP2024532457 A JP 2024532457A JP 2024532457 A JP2024532457 A JP 2024532457A JP 2024543967 A5 JP2024543967 A5 JP 2024543967A5
Authority
JP
Japan
Prior art keywords
group
alkyl
membered
cancer
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/083954 external-priority patent/WO2023099624A1/en
Publication of JP2024543967A publication Critical patent/JP2024543967A/ja
Publication of JP2024543967A5 publication Critical patent/JP2024543967A5/ja
Pending legal-status Critical Current

Links

JP2024532457A 2021-12-01 2022-11-30 ガン処置のための環化2-アミノ-3-シアノチオフェン及び誘導体 Pending JP2024543967A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163284778P 2021-12-01 2021-12-01
US202163284754P 2021-12-01 2021-12-01
US63/284,754 2021-12-01
US63/284,778 2021-12-01
PCT/EP2022/083954 WO2023099624A1 (en) 2021-12-01 2022-11-30 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024543967A JP2024543967A (ja) 2024-11-26
JP2024543967A5 true JP2024543967A5 (cg-RX-API-DMAC7.html) 2025-12-08

Family

ID=84536046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532457A Pending JP2024543967A (ja) 2021-12-01 2022-11-30 ガン処置のための環化2-アミノ-3-シアノチオフェン及び誘導体

Country Status (17)

Country Link
US (2) US12060367B2 (cg-RX-API-DMAC7.html)
EP (1) EP4441055A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543967A (cg-RX-API-DMAC7.html)
KR (1) KR20240128852A (cg-RX-API-DMAC7.html)
CN (1) CN119841847A (cg-RX-API-DMAC7.html)
AU (1) AU2022402390A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240980A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001617A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007014A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240233A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000101A (cg-RX-API-DMAC7.html)
IL (1) IL312905A (cg-RX-API-DMAC7.html)
JO (1) JOP20240124A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024006681A (cg-RX-API-DMAC7.html)
PE (1) PE20241356A1 (cg-RX-API-DMAC7.html)
TW (1) TW202337431A (cg-RX-API-DMAC7.html)
WO (1) WO2023099624A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
CN120265617A (zh) 2022-11-30 2025-07-04 勃林格殷格翰国际有限公司 制备螺环kras抑制剂的方法及中间体
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
US20250019385A1 (en) * 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2024255795A1 (en) * 2023-06-14 2024-12-19 Insilico Medicine Ip Limited Kras inhibitors and uses thereof
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260054710A (ko) 2023-08-17 2026-04-22 트리라인 바이오사이언시스, 인크. 스피로시클릭 디히드로피라노피리미딘 KRas 저해제
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
CN117946135A (zh) * 2024-01-24 2024-04-30 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025190158A1 (zh) * 2024-03-14 2025-09-18 四川科伦博泰生物医药股份有限公司 螺环化合物、其制备方法及用途
WO2025190342A1 (zh) * 2024-03-15 2025-09-18 苏州浦合医药科技有限公司 螺环化合物作为kras突变体抑制剂
WO2025201480A1 (zh) * 2024-03-28 2025-10-02 苏州浦合医药科技有限公司 螺环化合物作为kras突变体抑制剂
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202606711A (zh) * 2024-06-19 2026-02-16 香港商英矽智能科技知識產權有限公司 作為kras抑制劑的新化合物及其用途
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026007740A1 (zh) * 2024-07-04 2026-01-08 四川科伦博泰生物医药股份有限公司 螺环化合物、其制备方法及用途
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026114957A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer
US20260146050A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes
US20260146049A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2026114918A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras inhibitors for the treatment of cancer
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
MA37405A1 (fr) 2012-03-14 2016-03-31 Lupin Ltd Composés hétérocyclyle
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
MX380928B (es) 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
JP6577958B2 (ja) 2014-04-11 2019-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ[3H−インドール−3,2’−ピロリジン]−2(1H)−オン誘導体およびMDM2−p53阻害剤としてのそれらの使用
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
JP6591532B2 (ja) 2014-08-21 2019-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング MDM2−p53阻害剤としての新しいスピロ[3H−インドール−3,2’−ピロリジン]−2(1H)−オン化合物および誘導体
HUE054985T2 (hu) 2015-10-09 2021-11-29 Boehringer Ingelheim Int Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
MX2019006299A (es) 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
PL3728254T3 (pl) 2017-12-21 2023-06-12 Boehringer Ingelheim International Gmbh Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
EP3781565A1 (en) 2018-04-18 2021-02-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
BR112021001709A2 (pt) * 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020177629A1 (zh) 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物,其制法与医药上的用途
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CA3141604A1 (en) 2019-05-20 2020-11-26 1200 Pharma Llc Kras g12c inhibitors and uses thereof
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CR20220258A (es) * 2019-12-11 2022-07-03 Lilly Co Eli Inhibidores de kras g12c
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
WO2021139748A1 (en) 2020-01-08 2021-07-15 Ascentage Pharma (Suzhou) Co., Ltd. Spirocyclic tetrahydroquinazolines
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
TWI894229B (zh) 2020-03-16 2025-08-21 瑞士商諾華公司 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
CN113683616B (zh) 2020-05-18 2025-12-30 广州百霆医药科技有限公司 Kras g12c突变蛋白抑制剂
CN116034106B (zh) 2020-06-02 2025-11-04 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
EP4441050A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441051A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US20230227470A1 (en) * 2021-12-01 2023-07-20 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340209A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物

Similar Documents

Publication Publication Date Title
JP2024542692A5 (cg-RX-API-DMAC7.html)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP2024516997A5 (cg-RX-API-DMAC7.html)
RU2017125025A (ru) Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
JP2020517616A5 (cg-RX-API-DMAC7.html)
JP2014524441A5 (cg-RX-API-DMAC7.html)
JP2010523670A5 (cg-RX-API-DMAC7.html)
RU2014153627A (ru) Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ
CN115605479A (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2014513704A5 (cg-RX-API-DMAC7.html)
JP2008525417A5 (cg-RX-API-DMAC7.html)
JP2017505762A5 (cg-RX-API-DMAC7.html)
JP2008528467A5 (cg-RX-API-DMAC7.html)
JP2010526814A5 (cg-RX-API-DMAC7.html)
JP2007511504A5 (cg-RX-API-DMAC7.html)
JPWO2020032105A5 (cg-RX-API-DMAC7.html)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
RU2018104702A (ru) Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
JP2013516393A5 (cg-RX-API-DMAC7.html)
JP2011522889A5 (cg-RX-API-DMAC7.html)
JP2005535586A5 (cg-RX-API-DMAC7.html)
JPWO2019189732A5 (cg-RX-API-DMAC7.html)
JP2014518544A5 (cg-RX-API-DMAC7.html)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение